Coxibs and cancer prevention.

Area of Science:

• Oncology and Preventive Medicine
• Gastroenterology

Background:

• Cancer prevention is a growing focus in healthcare, with colorectal cancer (CRC) being a major public health concern due to high incidence and mortality rates.
• Chemopreventive agents aim to inhibit, delay, or reverse carcinogenesis, offering new strategies for cancer control.
• Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) show potential in CRC prevention but are limited by gastrointestinal toxicity.

Purpose of the Study:

• To explore the role of chemopreventive agents, specifically selective cyclooxygenase-2 (COX-2) inhibitors, in the prevention of colorectal cancer.
• To address the challenges and missing components in the chemoprevention of CRC, including patient selection, drug choice, dosage, and duration.

Main Methods:

• Review of existing evidence on NSAIDs and selective COX-2 inhibitors in CRC chemoprevention.
• Analysis of the gastrointestinal safety profiles and potential cardiovascular risks associated with these agents.
• Discussion of the current limitations and future directions for CRC prevention strategies.

Main Results:

• Evidence suggests an inverse relationship between NSAID use and CRC incidence/mortality.
• Selective COX-2 inhibitors offer a favorable gastrointestinal safety profile compared to traditional NSAIDs.
• Concerns exist regarding potential cardiovascular risks of selective COX-2 inhibitors due to effects on prostacyclin and thromboxane A2 production.

Conclusions:

• Selective COX-2 inhibitors are attractive for CRC chemoprevention due to improved gastrointestinal safety.
• Further research is needed to determine optimal patient selection, drug choice, dosage, and duration for effective and safe CRC prevention.
• Integrating these chemopreventive strategies into comprehensive cancer prevention efforts is crucial for potentially making CRC a preventable disease.